Getting to the point in point-of-care diagnostics for tuberculosis
Elisa H. Ignatius,1,2 Keira A. Cohen,3 and William R. Bishai1
1Division of Infectious Diseases,
2Division of Clinical Pharmacology, and
3Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: William R. Bishai, 1550 Orleans Street, CRB2 Room 108, Baltimore, Maryland 21287, USA. Phone: 410.955.3507; Email: wbishai@jhmi.edu.
Find articles by
Ignatius, E.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Infectious Diseases,
2Division of Clinical Pharmacology, and
3Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: William R. Bishai, 1550 Orleans Street, CRB2 Room 108, Baltimore, Maryland 21287, USA. Phone: 410.955.3507; Email: wbishai@jhmi.edu.
Find articles by
Cohen, K.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Infectious Diseases,
2Division of Clinical Pharmacology, and
3Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: William R. Bishai, 1550 Orleans Street, CRB2 Room 108, Baltimore, Maryland 21287, USA. Phone: 410.955.3507; Email: wbishai@jhmi.edu.
Find articles by
Bishai, W.
in:
JCI
|
PubMed
|
Google Scholar
|
First published September 28, 2020 - More info
© 2020 American Society for Clinical Investigation
Tuberculosis (TB) continues to affect over 10 million people per year worldwide. Despite advances in diagnosis, smear microscopy insufficiently detects pulmonary disease, with test result reporting taking longer than a day. While urine assays to detect the lipopolysaccharide lipoarabinomannan (LAM), present in mycobacterial cell walls, can provide results within minutes, the currently available assay has low sensitivity and its application is limited to patients with HIV suspected of having TB. In this issue of the JCI, Broger and Nicol et al. investigated 3 rapid urine tests in 372 ambulatory HIV-negative individuals suspected of having TB in South Africa and Peru. FujiLAM emerged as a rapid test to confirm TB diagnosis in the HIV-seronegative population. This study shows that FujiLAM has considerable potential to reshape the TB diagnostics landscape, making diagnosis and treatment in one office visit a reality for TB.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- JCI This Month subscription
- $135
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $195.
Copyright © 2020 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)